Not intended for US, Canada or UK-based media
- Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers
- Merck will receive an upfront payment of EUR300 million and is eligible for potential development milestone payments of up to EUR500 million triggered by data from the M7824 lung cancer program, plus future approval and commercial milestones of up to EUR2.9 billion for a total potential deal value of up to EUR3.7 billion
Merck, a leading science and technology company, and GSK, a science-led global healthcare company, today announced that the companies have entered into a global strategic alliance to jointly develop and commercialize M7824 (bintrafusp alfa*). M7824 is an investigational bifunctional fusion protein immunotherapy that is currently in clinical development, including potential registration studies, for multiple difficult-to-treat cancers. This includes a Phase II trial to investigate M7824 compared with pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).
To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/8491551-merck-and-gsk-announce-global-alliance
M7824 is designed to simultaneously target two immuno-suppressive pathways, transforming growth factor-beta (TGF-beta) trap and an anti-programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. Bifunctional antibodies aim to increase efficacy above and beyond that achieved with individual therapies or combinations of individual therapies.[1] M7824 has the potential to offer new ways to fight difficult-to-treat cancers beyond the established PD-1/PD-L1 class. In addition to use as a single agent, M7824 is also being considered for use in combination with other assets from the pipelines of both companies.
"Our bifunctional fusion protein M7824 has the potential to bring new answers to patients living with cancer. Together with GSK we aim to drive a paradigm shift in the treatment of cancer as the leader in this novel class of immunotherapies," said Belen Garijo, Member of the Executive Board and CEO Healthcare of Merck. "GSK clearly emerged as the ideal partner due to their strong commitment to oncology, and the complementary talent and capabilities they will bring to our alliance. We now look forward to harnessing the full potential of M7824 across a broad range of cancer indications as we continue to advance our oncology portfolio."
"Despite recent medical advances, many patients with difficult-to-treat cancers don't currently benefit from immuno-oncology therapies leaving them with limited treatment options. M7824 brings together two different biological functions in a single molecule and we have observed encouraging clinical results in treating certain cancer patients, particularly those people with non-small cell lung cancer," said Hal Barron, Chief Scientific Officer and President R&D, GSK. "I'm excited by the potential impact this first-in-class immunotherapy could have on the lives of cancer patients."
Merck will receive an upfront payment of EUR300 million and is eligible for potential development milestone payments of up to EUR500 million triggered by data from the M7824 lung cancer program. Merck will also be eligible
